Insmed (NASDAQ:INSM) Now Covered by Analysts at William Blair

Key Points

• William Blair has initiated coverage of Insmed (NASDAQ: INSM) with an "outperform" rating, signaling confidence in the company's stock performance.
• Several analysts, including those from Royal Bank Of Canada and Goldman Sachs, have raised their price targets on Insmed’s stock, with an average target price now at $129.57.
• Insmed reported a quarterly earnings miss, with ($1.70) EPS against a consensus estimate of ($1.30), despite a 18.9% year-over-year revenue increase to $107.42 million.

Analysts at William Blair began coverage on shares of Insmed (NASDAQ:INSM - Get Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The brokerage set an "outperform" rating on the biopharmaceutical company's stock.

A number of other analysts have also weighed in on INSM. Royal Bank Of Canada upped their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Leerink Partners upped their price target on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. The Goldman Sachs Group upped their price target on shares of Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Wells Fargo & Company upped their price target on shares of Insmed from $130.00 to $140.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 12th. Finally, Truist Financial upped their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Sixteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $129.57.

Insmed Price Performance

NASDAQ INSM opened at $127.21 on Wednesday. The company has a 50-day moving average price of $105.47 and a two-hundred day moving average price of $84.62. Insmed has a 52 week low of $60.40 and a 52 week high of $130.13. The stock has a market cap of $26.89 billion, a price-to-earnings ratio of -22.28 and a beta of 0.95. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Analysts forecast that Insmed will post -4.56 EPS for the current year.

Insider Activity

In related news, CEO William Lewis sold 6,830 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $102.37, for a total value of $699,187.10. Following the completion of the sale, the chief executive officer owned 233,924 shares in the company, valued at approximately $23,946,799.88. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider owned 89,407 shares in the company, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 497,829 shares of company stock worth $47,778,638 in the last quarter. Insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Hilltop National Bank acquired a new position in Insmed in the 2nd quarter valued at approximately $28,000. ORG Partners LLC increased its stake in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 196 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Insmed during the 2nd quarter worth $33,000. Cullen Frost Bankers Inc. increased its stake in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the last quarter. Finally, Elequin Capital LP acquired a new position in shares of Insmed during the 4th quarter worth $28,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.